Shares of Fresh Tracks Therapeutics, a clinical-stage pharmaceutical company, are up 70% or $1.22 per share in late trading on Tuesday to approximately $3.05 per share after the company announced it was evaluating FRTX-02 in healthy subjects, and saying the board approved a strategic review. "FRTX-02 is a potent, highly selective, and orally bioavailable potential first-in-class DYRK1A inhibitor that aims to restore immune balance by modulating both adaptive and innate immune responses in patients with autoimmune and inflammatory diseases. In parallel, the Company’s Board of Directors approved a comprehensive process to explore and evaluate strategic options to progress the development of its novel pipeline to maximize shareholder value," said the company in a release
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FRTX:
- Fresh Tracks Therapeutics Plunges despite Positive Phase 1 Results
- Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02
- Fresh Tracks appoints Andrew Sklawer as CEO
- Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer
- Fresh Tracks announces FRTX-02 is potent and selective inhibitor of DYRK1A
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue